- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Skin Cancer
Volume 2012 (2012), Article ID 621968, 8 pages
Germ Cell Proteins in Melanoma: Prognosis, Diagnosis, Treatment, and Theories on Expression
1Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA
2Anna Fund Melanoma Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Room 912, BRB, 1501 NW 10th Avenue, Miami, FL 33136, USA
3Department of Dermatology and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Room 912, BRB, 1501 NW 10th Avenue, Miami, FL 33136, USA
Received 30 June 2012; Accepted 16 October 2012
Academic Editor: Mohammed Kashani-Sabet
Copyright © 2012 Ashley M. Rosa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Knuth, T. Wolfel, E. Klehmann, T. Boon, and K. H. Meyer zum Buschenfelde, “Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 8, pp. 2804–2808, 1989.
- L. J. Old and Y. T. Chen, “New paths in human cancer serology,” Journal of Experimental Medicine, vol. 187, no. 8, pp. 1163–1167, 1998.
- M. J. Scanlan, A. J. Simpson, and L. J. Old, “The cancer/testis genes: review, standardization, and commentary,” Cancer Immunity, vol. 4, p. 1, 2004.
- A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old, “Cancer/testis antigens, gametogenesis and cancer,” Nature Reviews Cancer, vol. 5, no. 8, pp. 615–625, 2005.
- L. G. Almeida, N. J. Sakabe, A. R. de Oliveira et al., “CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens,” Nucleic Acids Research, vol. 37, no. 1, pp. D816–D819, 2009.
- J. M. Grichnik, “Melanoma, nevogenesis, and stem cell biology,” Journal of Investigative Dermatology, vol. 128, no. 10, pp. 2365–2380, 2008.
- A. S. Kondrashov, “Deleterious mutations and the evolution of sexual reproduction,” Nature, vol. 336, no. 6198, pp. 435–440, 1988.
- A. Forche, D. Abbey, T. Pisithkul et al., “Stress alters rates and types of loss of heterozygosity in candida albicans,” MBio, vol. 2, no. 4, 2011.
- S. M. Rosenberg, “Stress-induced loss of heterozygosity in candida: a possible missing link in the ability to evolve,” MBio, vol. 2, no. 5, 2011.
- A. Walter, M. J. Barysch, S. Behnke et al., “Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas,” Clinical Cancer Research, vol. 16, no. 14, pp. 3562–3570, 2010.
- E. Fratta, S. Coral, A. Covre et al., “The biology of cancer testis antigens: putative function, regulation and therapeutic potential,” Molecular Oncology, vol. 5, no. 2, pp. 164–182, 2011.
- E. R. Farmer, R. Gonin, and M. P. Hanna, “Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists,” Human Pathology, vol. 27, no. 6, pp. 528–531, 1996.
- S. W. McCarthy and R. A. Scolyer, “Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors,” Ochsner Journal, vol. 10, no. 2, pp. 66–74, 2010.
- M. Lüftl, G. Schuler, and A. A. Jungbluth, “Melanoma or not? Cancer testis antigens may help,” British Journal of Dermatology, vol. 151, no. 6, pp. 1213–1218, 2004.
- V. Davids, S. H. Kidson, and G. S. Hanekom, “Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate,” Journal of Clinical Pathology, vol. 56, no. 1, pp. 43–51, 2003.
- D. V. Kazakov, H. Kutzner, A. Rütten et al., “The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions,” American Journal of Dermatopathology, vol. 26, no. 2, pp. 102–107, 2004.
- M. Salemi, A. E. Calogero, E. Vicari et al., “A high percentage of skin melanoma cells expresses SPANX proteins,” American Journal of Dermatopathology, vol. 31, no. 2, pp. 182–186, 2009.
- J. Soikkeli, M. Lukk, P. Nummela et al., “Systematic search for the best gene expression markers for melanoma micrometastasis detection,” Journal of Pathology, vol. 213, no. 2, pp. 180–189, 2007.
- H. Ikeda, B. Lethé, F. Lehmann et al., “Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor,” Immunity, vol. 6, no. 2, pp. 199–208, 1997.
- C. Haqq, M. Nosrati, D. Sudilovsky et al., “The gene expression signatures of melanoma progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6092–6097, 2005.
- S. Svobodová, J. Browning, D. MacGregor et al., “Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate,” European Journal of Cancer, vol. 47, no. 3, pp. 460–469, 2011.
- I. N. Mikhaylova, D. A. Kovalevsky, L. F. Morozova et al., “Cancer/testis genes expression in human melanoma cell lines,” Melanoma Research, vol. 18, no. 5, pp. 303–313, 2008.
- M. Vourc'H-Jourdain, C. Volteau, J. M. Nguyen, A. Khammari, and B. Dreno, “Melanoma gene expression and clinical course,” Archives of Dermatological Research, vol. 301, no. 9, pp. 673–679, 2009.
- E. F. Velazquez, A. A. Jungbluth, M. Yancovitz et al., “Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic factors,” Cancer Immunity, vol. 7, no. 11, 2007.
- C. Barrow, J. Browning, D. MacGregor et al., “Tumor antigen expression in melanoma varies according to antigen and stage,” Clinical Cancer Research, vol. 12, no. 3 I, pp. 764–771, 2006.
- J. S. Goydos, M. Patel, and W. Shih, “NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma,” Journal of Surgical Research, vol. 98, no. 2, pp. 76–80, 2001.
- A. J. W. Zendman, A. A. Van Kraats, A. I. Den Hollander, U. H. Weidle, D. J. Ruiter, and G. N. P. Van Muijen, “Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis,” International Journal of Cancer, vol. 97, no. 2, pp. 195–204, 2002.
- C. Roeder, B. Schuler-Thurner, S. Berchtold et al., “MAGE-A3 is a frequent tumor antigen of metastasized melanoma,” Archives of Dermatological Research, vol. 296, no. 7, pp. 314–319, 2005.
- A. Curioni-Fontecedro, N. Nuber, D. Mihic-Probst et al., “Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients,” PLoS ONE, vol. 6, no. 6, Article ID e21418, 2011.
- P. F. Ferrucci, G. Tosti, A. di Pietro et al., “Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment,” Current Topics in Medicinal Chemistry, vol. 12, no. 1, pp. 11–31, 2012.
- O. L. Caballero and Y. T. Chen, “Cancer/testis (CT) antigens: potential targets for immunotherapy,” Cancer Science, vol. 100, no. 11, pp. 2014–2021, 2009.
- M. Sang, Y. Lian, X. Zhou, and B. Shan, “MAGE-A family: attractive targets for cancer immunotherapy,” Vaccine, vol. 29, no. 47, pp. 8496–8500, 2011.
- M. Schwabe and M. Lübbert, “Epigenetic lesions in malignant melanoma,” Current Pharmaceutical Biotechnology, vol. 8, no. 6, pp. 382–387, 2007.
- B. Yang, J. Wu, N. Maddodi, Y. Ma, V. Setaluri, and B. J. Longley, “Epigenetic control of MAGE gene expression by the KIT tyrosine kinase,” Journal of Investigative Dermatology, vol. 127, no. 9, pp. 2123–2128, 2007.
- P. F. Robbins, R. A. Morgan, S. A. Feldman et al., “Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 917–924, 2011.
- J. H. Park, G. H. Kong, and S. W. Lee, “hMAGE-A1 overexpression reduces TNF-α cytotoxicity in ME-180 cells,” Molecules and Cells, vol. 14, no. 1, pp. 122–129, 2002.
- B. Zbytek, J. A. Carlson, J. Granese, J. Ross, M. Mihm, and A. Slominski, “Current concepts of metastasis in melanoma,” Expert Review of Dermatology, vol. 3, no. 5, pp. 569–585, 2008.
- B. Yang, S. M. O'Herrin, J. Wu et al., “MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines,” Cancer Research, vol. 67, no. 20, pp. 9954–9962, 2007.
- M. T. Epping, L. Wang, M. J. Edel, L. Carlée, M. Hernandez, and R. Bernards, “The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling,” Cell, vol. 122, no. 6, pp. 835–847, 2005.
- S. Laduron, R. Deplus, S. Zhou et al., “MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription,” Nucleic Acids Research, vol. 32, no. 14, pp. 4340–4350, 2004.
- M. F. Gjerstorff, L. E. Johansen, O. Nielsen, K. Kock, and H. J. Ditzel, “Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy,” British Journal of Cancer, vol. 94, no. 12, pp. 1864–1873, 2006.
- M. Koslowski, O. Türeci, C. Bell et al., “Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer,” Cancer Research, vol. 62, no. 22, pp. 6750–6755, 2002.
- A. L. Marston and A. Amon, “Meiosis: cell-cycle controls shuffle and deal,” Nature Reviews Molecular Cell Biology, vol. 5, no. 12, pp. 983–997, 2004.
- M. A. Blasco, “Telomeres and cancer: a tale with many endings,” Current Opinion in Genetics and Development, vol. 13, no. 1, pp. 70–76, 2003.
- N. R. Dos Santos, R. Torensma, T. J. De Vries et al., “Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines,” Cancer Research, vol. 60, no. 6, pp. 1654–1662, 2000.
- A. V. Bazhin, N. Wiedemann, M. Schnölzer, D. Schadendorf, and S. B. Eichmüller, “Expression of GAGE family proteins in malignant melanoma,” Cancer Letters, vol. 251, no. 2, pp. 258–267, 2007.
- A. A. Jungbluth, Y.-T. Chen, E. Stockert et al., “Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues,” International Journal of Cancer, vol. 92, no. 6, pp. 856–860, 2001.
- K. Shakib, J. T. Norman, L. G. Fine, L. R. Brown, and J. Godovac-Zimmermann, “Proteomics profiling of nuclear proteins for kidney fibroblasts suggests hypoxia, meiosis, and cancer may meet in the nucleus,” Proteomics, vol. 5, no. 11, pp. 2819–2838, 2005.
- A. Roesch, M. Fukunaga-Kalabis, E. C. Schmidt et al., “A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth,” Cell, vol. 141, no. 4, pp. 583–594, 2010.
- A. Janic, L. Mendizabal, S. Llamazares, D. Rossell, and C. Gonzalez, “Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila,” Science, vol. 330, no. 6012, pp. 1824–1827, 2010.
- N. Bhatia, B. Yang, T. Z. Xiao, N. Peters, M. F. Hoffmann, and B. J. Longley, “Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1,” Archives of Biochemistry and Biophysics, vol. 508, no. 2, pp. 217–221, 2011.
- B. Yang, S. O'Herrin, J. Wu et al., “Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo,” Journal of Investigative Dermatology, vol. 127, no. 2, pp. 267–275, 2007.
- C. S. L. Müller, “Notch signaling and malignant melanoma,” Advances in Experimental Medicine and Biology, vol. 727, pp. 258–264, 2012.
- F. Boussouar and M. Benahmed, “Lactate and energy metabolism in male germ cells,” Trends in Endocrinology and Metabolism, vol. 15, no. 7, pp. 345–350, 2004.
- O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956.
- D. A. Scott, A. D. Richardson, F. V. Filipp et al., “Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect,” Journal of Biological Chemistry, vol. 286, no. 49, pp. 42626–42634, 2011.
- E. Goldberg, “Reproductive implications of LDH-C4 and other testis-specific isozymes,” Experimental and Clinical Immunogenetics, vol. 2, no. 2, pp. 120–124, 1985.
- O. Türeci, U. Sahin, C. Zwick, M. Koslowski, G. Seitz, and M. Pfreundschuh, “Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 9, pp. 5211–5216, 1998.
- Y. T. Chen, C. A. Venditti, G. Theiler et al., “Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein,” Cancer Immunity, vol. 5, p. 9, 2005.
- S. Bekaert, H. Derradji, and S. Baatout, “Telomere biology in mammalian germ cells and during development,” Developmental Biology, vol. 274, no. 1, pp. 15–30, 2004.
- T. Batinac, I. Hadžisejdić, G. Brumini, A. Ružić, B. Vojniković, and G. Zamolo, “Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions,” Collegium Antropologicum, vol. 31, no. 1, supplement, pp. 17–22, 2007.
- J. K. Soo, A. D. Mackenzie Ross, D. M. Kallenberg et al., “Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression,” Pigment Cell and Melanoma Research, vol. 24, no. 3, pp. 490–503, 2011.